Status:
RECRUITING
Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial
Lead Sponsor:
OCEAN-SHD Study Group
Conditions:
Aortic Stenosis
TAVI(Transcatheter Aortic Valve Implantation)
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
Aspirin group: Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period. Non-antithrombotic group: No antithrombotic agents will ...
Eligibility Criteria
Inclusion
- Patients who underwent transfemoral TAVI for aortic stenosis
- Patients aged 20 years or older at the time of informed consent
- Patients who have a thorough understanding of the subject of the study and who have agreed in writing to participate in the study
Exclusion
- Those with perioperative complications at the time of TAVI (conversion to open heart surgery, coronary artery occlusion, annulus rupture, cardiac tamponade, vascular dissection, cerebral infarction/cerebral hemorrhage, new atrial fibrillation, new atrioventricular block)
- Individuals requiring antiplatelet agents for reasons other than TAVI (history of myocardial infraction, history of PCI（Percutaneous Coronary Intervention）, history of EVT（EndoVascular Treatment）, history of cerebral infraction and transient ischaemic stroke, with significant coronary artery narrowing, with high-grade carotid artery narrowing, and others judged as requiring antiplatelet therapy by the chief researcher or a sub-investigator)
- Patients requiring oral anticoagulants (patients with atrial fibrillation, history of pulmonary embolism or deep venous thrombosis, and other patients who are deemed to require anticoagulation therapy by the investigator or coinvestigator)
- Patients with eGFR（estimated Glomerular Filtration Rate） \<30 and patients on hemodialysis/peritoneal dialysis.
- Patients with a history of valve replacement in the heart valves.
- Patients who are pregnant, have childbearing potential, wish to become pregnant, or are breastfeeding.
- Patients who have a concomitant medical illness associated with expected survival less than one year.
- Patients who have the contraindications for aspirin.
- Patients with a diagnosis of severe allergy to aspirin or a history of hypersensitivity.
- Patients requiring a legally acceptable representative, patients unable to obtain written informed consent, or patients unable to understand the outline or purpose of the study.
- Other patients for whom the principal investigator or the coinvestigator judges the participation in the study inappropriate.
Key Trial Info
Start Date :
April 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06007222
Start Date
April 6 2023
End Date
December 31 2027
Last Update
September 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Keio University Hospital
Shinjuku, Tokyo, Japan, 160-8582